About: Clinical Characteristics and Outcomes of Type 2 Diabetes Patients Infected with COVID-19: A Retrospective Study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical Characteristics and Outcomes of Type 2 Diabetes Patients Infected with COVID-19: A Retrospective Study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Clinical Characteristics and Outcomes of Type 2 Diabetes Patients Infected with COVID-19: A Retrospective Study
Creator	Chen, Yingyu Jin, Yinghua Li, J Zhang, Z Guo, Jiao Chen, J Chen, Y Jin, Y Gong, Xiao Chen, Jiankun Gong, X Guo, J Li, Jiqiang Rong, X Rong, Xianglu Ye, D Ye, Dewei Zhang, Zhongde
Source	Elsevier; Medline; PMC
abstract	Diabetes and its related metabolic disorders have been reported as the leading comorbidities in patients with coronavirus disease 2019 (COVID-19). This clinical study aims to investigate the clinical features, radiographic and laboratory tests, complications, treatments, and clinical outcomes in COVID-19 patients with or without diabetes. This retrospective study included 208 hospitalized patients (≥ 45 years old) with laboratory-confirmed COVID-19 during the period between 12 January and 25 March 2020. Information from the medical record, including clinical features, radiographic and laboratory tests, complications, treatments, and clinical outcomes, were extracted for the analysis. 96 (46.2%) patients had comorbidity with type 2 diabetes. In COVID-19 patients with type 2 diabetes, the coexistence of hypertension (58.3% vs. 31.2%), coronary heart disease (17.1% vs. 8.0%), and chronic kidney diseases (6.2% vs. 0%) was significantly higher than in COVID-19 patients without type 2 diabetes. The frequency and degree of abnormalities in computed tomography (CT) chest scans in COVID-19 patients with type 2 diabetes were markedly increased, including ground-glass opacity (85.6% vs. 64.9%, P < 0.001) and bilateral patchy shadowing (76.7% vs. 37.8%, P < 0.001). In addition, the levels of blood glucose (7.23 mmol·L(-1) (interquartile range (IQR): 5.80–9.29) vs. 5.46 mmol·L(-1) (IQR: 5.00–6.46)), blood low-density lipoprotein cholesterol (LDL-C) (2.21 mmol·L(-1) (IQR: 1.67–2.76) vs. 1.75 mmol·L(-1) (IQR: 1.27–2.01)), and systolic pressure (130 mmHg (IQR: 120–142) vs. 122 mmHg (IQR: 110–137), P = 0.001) in COVID-19 patients with diabetes were significantly higher than in patients without diabetes (P < 0.001). The coexistence of type 2 diabetes and other metabolic disorders is common in patients with COVID-19, which may potentiate the morbidity and aggravate COVID-19 progression. Optimal management of the metabolic hemostasis of glucose and lipids is the key to ensuring better clinical outcomes. Increased clinical vigilance is warranted for COVID-19 patients with diabetes and other metabolic diseases that are fundamental and chronic conditions.
has issue date	2020-06-27(xsd:dateTime)
bibo:doi	10.1016/j.eng.2020.05.017
bibo:pmid	32837747
has license	no-cc
sha1sum (hex)	0c0e900e925711bb1cac100c94e3c2a33f37b631
schema:url	https://doi.org/10.1016/j.eng.2020.05.017
resource representing a document's title	Clinical Characteristics and Outcomes of Type 2 Diabetes Patients Infected with COVID-19: A Retrospective Study
has PubMed Central identifier	PMC7320669
has PubMed identifier	32837747
schema:publication	Engineering (Beijing)
resource representing a document's body	covid:0c0e900e925711bb1cac100c94e3c2a33f37b631#body_text
is schema:about of	named entity 'Diabetes' named entity 'bilateral' named entity 'extracted' named entity 'features' named entity 'features' named entity 'Study' named entity 'Type 2 Diabetes' named entity 'COVID' named entity 'BILATERAL' named entity 'COMPUTED TOMOGRAPHY' named entity 'SCANS' named entity 'DIABETES' named entity 'MEDICAL RECORD' named entity '287' named entity 'YEARS' named entity 'CLINICAL STUDY' named entity 'PATIENTS' named entity 'AIMS' named entity 'COMORBIDITY' named entity 'INCLUDING' named entity 'FREQUENCY' named entity 'HAVE' named entity 'GROUND-GLASS OPACITY' named entity 'RETROSPECTIVE STUDY' covid:arg/0c0e900e925711bb1cac100c94e3c2a33f37b631 named entity 'ground-glass opacity' named entity 'addition' named entity 'diabetes' named entity 'non-diabetic' named entity 'end point' named entity 'clinical outcomes' named entity 'COVID-19' named entity 'homeostasis' named entity 'COVID-19.' named entity 'thrombocytopenia' named entity 'lipid metabolism' named entity 'diabetic' named entity 'comorbidity' named entity 'metabolic diseases' named entity 'ICU' named entity 'coagulation' named entity 'muscle pain' named entity 'diabetes' named entity 'critically ill' named entity 'coronary heart disease' named entity 'metabolism' named entity 'radiographic' named entity 'coronavirus disease 2019' named entity 'IgA' named entity 'metabolism of glucose' named entity 'International Diabetes Federation' named entity 'glucose' named entity 'COVID-19' named entity 'acupuncture' named entity 'China' named entity 'infection' named entity 'clinical outcomes' named entity 'ACE2' named entity 'COVID' named entity 'Diabetes' named entity 'autoimmunity' named entity 'pro-inflammatory' named entity 'glucocorticoids' named entity 'diabetic'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software